View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsValens 将来の成長Future 基準チェック /26主要情報113.4%収益成長率115.80%EPS成長率Pharmaceuticals 収益成長21.7%収益成長率55.2%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Jan 19+ 1 more updateSNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS).SNDL Inc. (NasdaqCM:SNDL) entered into an arrangement agreement to acquire remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) for CAD 94.2 million on August 22, 2022. Under the terms of the Agreement, Valens' shareholders will receive, for each Valens Share, 0.3334 of a common share of SNDL. The combined company will operate as SNDL Inc., and Valens shareholders will own approximately 9.5% of the pro forma entity. The Agreement provides for, among other things, customary support and non-solicitation covenants from Valens, including customary "fiduciary out" provisions that allow Valens to accept a superior proposal in certain circumstances and a five-business day "right to match period" in favour of SNDL. The Agreement also provides for the payment of a termination fee of CAD 8 million payable to SNDL by Valens in the event the Transaction is terminated in certain specified circumstances. The Transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act. The implementation of the Transaction will be subject to the approval of at least two thirds of the Valens Shares entitled to be voted by Valens shareholders and the approval of a simple majority of the Valens Shares entitled to be voted by Valens shareholders, other than Valens shareholders required to be excluded under applicable laws, at a special meeting expected to be convened by Valens by the end of November 2022 (the "Meeting"), Shares to be issued pursuant to the Arrangement shall have been approved for listing on Nasdaq, and the receipt of applicable orders from the Ontario Superior Court of Justice and applicable regulatory approvals, including under the Competition Act (Canada) and the applicable provincial liquor and cannabis regulators. Valens' board of directors has unanimously approved the Transaction after receiving the unanimous recommendation of a special committee of Valens directors (the "Special Committee"). Valens' board of directors has unanimously resolved to recommend that the shareholders of Valens vote in favour of the Transaction. SNDL’s Board of Directors also unanimously approved the Transaction. All directors and executive officers of Valens have entered into voting support agreements with SNDL pursuant to which, among other things, the parties have agreed to vote their Valens Shares in favour of the Transaction. The shareholders meeting of Valens is scheduled on November 29, 2022. As of November 22, 2022, both Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended that Valens shareholders (the “Valens Shareholders”) vote in favour of the arrangement. On November 29, 2022, shareholders of Valens approved the transaction. As of December 13, 2022, The Valens Company has been granted additional 180 calendar day grace period by Nasdaq to regain compliance with Minimum Bid Price rule. As a result of the extension, The Valens Company now has until June 12, 2023, to regain compliance with the Bid Price Requirement. The Ontario Superior Court of Justice (Commercial List) has granted a final order approving the transaction. The transaction is expected to close during January 2023. Together with incremental revenues from greater distribution of Valens products, it is estimated that the Transaction will deliver upwards of CAD 15 million of additional EBITDA on an annual run-rate basis through synergies and other strategic initiatives. Cormark Securities Inc. has provided a fairness opinion to the Special Committee of Valens that, subject to the assumptions, limitations and qualifications set out in such fairness opinion, the consideration to be received by Valens shareholders pursuant to the Transaction is fair from a financial point of view to Valens' shareholders. ATB Capital Markets Inc. is acting as financial advisor to SNDL. Ranjeev Dhillon and Rami Chalabi of McCarthy Tétrault LLP acting as legal counsels to SNDL. Cormark Securities Inc. is acting as financial advisor and Donald Belovich of Stikeman Elliott LLP is acting as legal counsel to Valens. Laurel Hill Advisory Group, LLC acted as information agent with a service fee of $50,000 (CAD 67,869) and Computershare Investor Services Inc. acted transfer agent to Valens. Marcum LLP acted as accountant while Odyssey Trust Company acted as transfer agent to SNDL. SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) on January 17, 2023. Frank Krasovec has been appointed to the Board of Directors of SNDL, effective January 17, 2023. The Board now consists of six directors. Zach George will continue to serve as Chief Executive Officer of SNDL and Tyler Robson, the former CEO of Valens, will join the leadership team as President of Cannabis. Andrew Stordeur, SNDL's former President and Chief Operating Officer has left the company effective January 13, 2023. Immediately prior to the effective date of the Transaction, SNDL owned an aggregate of 6.5 million Valens Shares, representing approximately 8.1% of the outstanding Valens Shares at such time. Following the closing of the Transaction, there are 260.7 million SNDL Shares outstanding, with existing SNDL Shareholders holding approximately 89.4% of such outstanding SNDL Shares and former Valens Shareholders holding approximately 10.6% of such outstanding SNDL Shares. The Valens Shares are expected to be delisted from the Toronto Stock Exchange.Reported Earnings • Jul 15Second quarter 2022 earnings released: CA$2.13 loss per share (vs CA$0.17 loss in 2Q 2021)Second quarter 2022 results: CA$2.13 loss per share (down from CA$0.17 loss in 2Q 2021). Revenue: CA$24.0m (up 28% from 2Q 2021). Net loss: CA$160.8m (loss widened CA$152.1m from 2Q 2021). Over the next year, revenue is forecast to grow 66%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 16 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Apr 27Independent Director recently bought €98k worth of stockOn the 21st of April, Andrew Cockwell bought around 90k shares on-market at roughly €1.09 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.0m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Apr 21Independent Director recently bought €70k worth of stockOn the 19th of April, Guy Beaudin bought around 65k shares on-market at roughly €1.08 per share. In the last 3 months, there was an even bigger purchase from another insider worth €91k. Insiders have collectively bought €6.9m more in shares than they have sold in the last 12 months.Reported Earnings • Apr 15First quarter 2022 earnings released: CA$0.38 loss per share (vs CA$0.14 loss in 1Q 2021)First quarter 2022 results: CA$0.38 loss per share (down from CA$0.14 loss in 1Q 2021). Revenue: CA$23.2m (up 16% from 1Q 2021). Net loss: CA$25.7m (loss widened 319% from 1Q 2021). Over the next year, revenue is forecast to grow 71%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Apr 08Independent Director recently bought €91k worth of stockOn the 5th of April, Andrew Cockwell bought around 47k shares on-market at roughly €1.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €6.7m more in shares than they have sold in the last 12 months.Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.88 loss per share (down from CA$0.49 loss in FY 2020). Revenue: CA$78.2m (down 6.7% from FY 2020). Net loss: CA$49.0m (loss widened 137% from FY 2020). Revenue missed analyst estimates by 3.3%. Over the next year, revenue is forecast to grow 78%, compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Oct 21CEO & Chairman recently bought €80k worth of stockOn the 18th of October, Andrew Robson bought around 59k shares on-market at roughly €1.35 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of €193k worth in shares.Reported Earnings • Oct 14Third quarter 2021 earnings released: CA$0.076 loss per share (vs CA$0.024 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$21.0m (up 16% from 3Q 2020). Net loss: CA$12.8m (loss widened 318% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Recent Insider Transactions • Aug 11Insider recently sold €75k worth of stockOn the 5th of August, Paolo Pero sold around 43k shares on-market at roughly €1.74 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €6.7m more than they sold in the last 12 months.Executive Departure • Jun 01Independent Director has left the companyOn the 25th of May, Nitin Kaushal's tenure as Independent Director ended after 2.7 years in the role. As of March 2021, Nitin personally held 60.00k shares (€104k worth at the time). A total of 4 executives have left over the last 12 months.Executive Departure • May 19Chief Financial Officer has left the companyOn the 17th of May, Christopher Buysen's tenure as Chief Financial Officer ended after 2.9 years in the role. As of December 2020, Christopher personally held 333.17k shares (€355k worth at the time). A total of 3 executives have left over the last 12 months.Recent Insider Transactions • Oct 30CEO & Chairman recently bought €66k worth of stockOn the 28th of October, Andrew Robson bought around 71k shares on-market at roughly €0.93 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Andrew has been a net seller over the last 12 months, reducing personal holdings by €909k.Is New 90 Day High Low • Oct 29New 90-day low: €0.92The company is down 30% from its price of €1.31 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.68 per share.Is New 90 Day High Low • Oct 06New 90-day low: €0.97The company is down 35% from its price of €1.50 on 08 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.61 per share.Is New 90 Day High Low • Sep 18New 90-day low: €1.22The company is down 25% from its price of €1.63 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.97 per share.お知らせ • Jul 07The Valens Company Inc. to Report Q2, 2020 Results on Jul 15, 2020The Valens Company Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Jul 15, 2020業績と収益の成長予測DB:7LV0 - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数11/30/2023172-21N/AN/A211/30/2022107-219N/AN/A28/31/202286-236-72-65N/A5/31/202287-221-81-72N/A2/28/202281-69-80-70N/A11/30/202178-49-64-47N/A8/31/202176-44-48-31N/A5/31/202173-35-45-21N/A2/28/202172-29-41-15N/A11/30/202084-21-47-16N/A8/31/2020980-53-21N/A5/31/2020979-37-12N/A2/29/2020882-37-5N/A11/30/201958-7-28-8N/A8/31/201927-18-25-8N/A5/31/201911-27-29-13N/A2/28/20192-19-17-11N/A11/30/20180-16-14-9N/A8/31/20180-9-11-6N/A5/31/20180-8-9-5N/A2/28/20180-7-4-2N/A11/30/20170-4-3-2N/A8/31/20170-11-2-1N/A5/31/20170-11-1-1N/A2/28/20170-9-1-1N/A11/30/20160-800N/A8/31/20160-100N/A5/31/20160-1N/A0N/A2/29/20160-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 7LV0今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 7LV0今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 7LV0今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 7LV0の収益 ( 55.2% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 7LV0の収益 ( 55.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7LV0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/01/19 22:33終値2023/01/17 00:00収益2022/08/31年間収益2021/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋The Valens Company Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関David KideckelATB CormarkKimberly Thompson-HedlinCanaccord GenuityJohn ChuDesjardins Securities Inc.4 その他のアナリストを表示
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
お知らせ • Jan 19+ 1 more updateSNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS).SNDL Inc. (NasdaqCM:SNDL) entered into an arrangement agreement to acquire remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) for CAD 94.2 million on August 22, 2022. Under the terms of the Agreement, Valens' shareholders will receive, for each Valens Share, 0.3334 of a common share of SNDL. The combined company will operate as SNDL Inc., and Valens shareholders will own approximately 9.5% of the pro forma entity. The Agreement provides for, among other things, customary support and non-solicitation covenants from Valens, including customary "fiduciary out" provisions that allow Valens to accept a superior proposal in certain circumstances and a five-business day "right to match period" in favour of SNDL. The Agreement also provides for the payment of a termination fee of CAD 8 million payable to SNDL by Valens in the event the Transaction is terminated in certain specified circumstances. The Transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act. The implementation of the Transaction will be subject to the approval of at least two thirds of the Valens Shares entitled to be voted by Valens shareholders and the approval of a simple majority of the Valens Shares entitled to be voted by Valens shareholders, other than Valens shareholders required to be excluded under applicable laws, at a special meeting expected to be convened by Valens by the end of November 2022 (the "Meeting"), Shares to be issued pursuant to the Arrangement shall have been approved for listing on Nasdaq, and the receipt of applicable orders from the Ontario Superior Court of Justice and applicable regulatory approvals, including under the Competition Act (Canada) and the applicable provincial liquor and cannabis regulators. Valens' board of directors has unanimously approved the Transaction after receiving the unanimous recommendation of a special committee of Valens directors (the "Special Committee"). Valens' board of directors has unanimously resolved to recommend that the shareholders of Valens vote in favour of the Transaction. SNDL’s Board of Directors also unanimously approved the Transaction. All directors and executive officers of Valens have entered into voting support agreements with SNDL pursuant to which, among other things, the parties have agreed to vote their Valens Shares in favour of the Transaction. The shareholders meeting of Valens is scheduled on November 29, 2022. As of November 22, 2022, both Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended that Valens shareholders (the “Valens Shareholders”) vote in favour of the arrangement. On November 29, 2022, shareholders of Valens approved the transaction. As of December 13, 2022, The Valens Company has been granted additional 180 calendar day grace period by Nasdaq to regain compliance with Minimum Bid Price rule. As a result of the extension, The Valens Company now has until June 12, 2023, to regain compliance with the Bid Price Requirement. The Ontario Superior Court of Justice (Commercial List) has granted a final order approving the transaction. The transaction is expected to close during January 2023. Together with incremental revenues from greater distribution of Valens products, it is estimated that the Transaction will deliver upwards of CAD 15 million of additional EBITDA on an annual run-rate basis through synergies and other strategic initiatives. Cormark Securities Inc. has provided a fairness opinion to the Special Committee of Valens that, subject to the assumptions, limitations and qualifications set out in such fairness opinion, the consideration to be received by Valens shareholders pursuant to the Transaction is fair from a financial point of view to Valens' shareholders. ATB Capital Markets Inc. is acting as financial advisor to SNDL. Ranjeev Dhillon and Rami Chalabi of McCarthy Tétrault LLP acting as legal counsels to SNDL. Cormark Securities Inc. is acting as financial advisor and Donald Belovich of Stikeman Elliott LLP is acting as legal counsel to Valens. Laurel Hill Advisory Group, LLC acted as information agent with a service fee of $50,000 (CAD 67,869) and Computershare Investor Services Inc. acted transfer agent to Valens. Marcum LLP acted as accountant while Odyssey Trust Company acted as transfer agent to SNDL. SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) on January 17, 2023. Frank Krasovec has been appointed to the Board of Directors of SNDL, effective January 17, 2023. The Board now consists of six directors. Zach George will continue to serve as Chief Executive Officer of SNDL and Tyler Robson, the former CEO of Valens, will join the leadership team as President of Cannabis. Andrew Stordeur, SNDL's former President and Chief Operating Officer has left the company effective January 13, 2023. Immediately prior to the effective date of the Transaction, SNDL owned an aggregate of 6.5 million Valens Shares, representing approximately 8.1% of the outstanding Valens Shares at such time. Following the closing of the Transaction, there are 260.7 million SNDL Shares outstanding, with existing SNDL Shareholders holding approximately 89.4% of such outstanding SNDL Shares and former Valens Shareholders holding approximately 10.6% of such outstanding SNDL Shares. The Valens Shares are expected to be delisted from the Toronto Stock Exchange.
Reported Earnings • Jul 15Second quarter 2022 earnings released: CA$2.13 loss per share (vs CA$0.17 loss in 2Q 2021)Second quarter 2022 results: CA$2.13 loss per share (down from CA$0.17 loss in 2Q 2021). Revenue: CA$24.0m (up 28% from 2Q 2021). Net loss: CA$160.8m (loss widened CA$152.1m from 2Q 2021). Over the next year, revenue is forecast to grow 66%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 16 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Apr 27Independent Director recently bought €98k worth of stockOn the 21st of April, Andrew Cockwell bought around 90k shares on-market at roughly €1.09 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.0m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Apr 21Independent Director recently bought €70k worth of stockOn the 19th of April, Guy Beaudin bought around 65k shares on-market at roughly €1.08 per share. In the last 3 months, there was an even bigger purchase from another insider worth €91k. Insiders have collectively bought €6.9m more in shares than they have sold in the last 12 months.
Reported Earnings • Apr 15First quarter 2022 earnings released: CA$0.38 loss per share (vs CA$0.14 loss in 1Q 2021)First quarter 2022 results: CA$0.38 loss per share (down from CA$0.14 loss in 1Q 2021). Revenue: CA$23.2m (up 16% from 1Q 2021). Net loss: CA$25.7m (loss widened 319% from 1Q 2021). Over the next year, revenue is forecast to grow 71%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Apr 08Independent Director recently bought €91k worth of stockOn the 5th of April, Andrew Cockwell bought around 47k shares on-market at roughly €1.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €6.7m more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.88 loss per share (down from CA$0.49 loss in FY 2020). Revenue: CA$78.2m (down 6.7% from FY 2020). Net loss: CA$49.0m (loss widened 137% from FY 2020). Revenue missed analyst estimates by 3.3%. Over the next year, revenue is forecast to grow 78%, compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Oct 21CEO & Chairman recently bought €80k worth of stockOn the 18th of October, Andrew Robson bought around 59k shares on-market at roughly €1.35 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of €193k worth in shares.
Reported Earnings • Oct 14Third quarter 2021 earnings released: CA$0.076 loss per share (vs CA$0.024 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$21.0m (up 16% from 3Q 2020). Net loss: CA$12.8m (loss widened 318% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Recent Insider Transactions • Aug 11Insider recently sold €75k worth of stockOn the 5th of August, Paolo Pero sold around 43k shares on-market at roughly €1.74 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €6.7m more than they sold in the last 12 months.
Executive Departure • Jun 01Independent Director has left the companyOn the 25th of May, Nitin Kaushal's tenure as Independent Director ended after 2.7 years in the role. As of March 2021, Nitin personally held 60.00k shares (€104k worth at the time). A total of 4 executives have left over the last 12 months.
Executive Departure • May 19Chief Financial Officer has left the companyOn the 17th of May, Christopher Buysen's tenure as Chief Financial Officer ended after 2.9 years in the role. As of December 2020, Christopher personally held 333.17k shares (€355k worth at the time). A total of 3 executives have left over the last 12 months.
Recent Insider Transactions • Oct 30CEO & Chairman recently bought €66k worth of stockOn the 28th of October, Andrew Robson bought around 71k shares on-market at roughly €0.93 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Andrew has been a net seller over the last 12 months, reducing personal holdings by €909k.
Is New 90 Day High Low • Oct 29New 90-day low: €0.92The company is down 30% from its price of €1.31 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.68 per share.
Is New 90 Day High Low • Oct 06New 90-day low: €0.97The company is down 35% from its price of €1.50 on 08 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.61 per share.
Is New 90 Day High Low • Sep 18New 90-day low: €1.22The company is down 25% from its price of €1.63 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.97 per share.
お知らせ • Jul 07The Valens Company Inc. to Report Q2, 2020 Results on Jul 15, 2020The Valens Company Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Jul 15, 2020